SynthesisEuropean heart journal2021
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- A Comprehensive Meta-Analysis of Bioadaptor Versus Drug-Eluting Stents in Randomised Trials With Exploratory Single-Arm Landmark Analyses.European journal of clinical investigation · 2026Pooled it
- Comparative effectiveness of ultrathin vs. standard strut drug-eluting stents: insights from a large-scale meta-analysis with extended follow-up.European journal of medical research · 2024Pooled it
- Long-term safety of ultrathin bioabsorbable-polymer sirolimus-eluting stents versus thin durable-polymer drug-eluting stents in acute coronary syndrome: A systematic review and meta-analysis.Clinical cardiology · 2023Pooled it
- Biodegradable Polymer Versus Polymer-Free Ultrathin Sirolimus-Eluting Stents in Complex Percutaneous Coronary Intervention: Post Hoc Analysis of the Stent Arm Registry From the HOST-IDEA Randomized Trial.Journal of the American Heart Association · 2026Trial
- Patients with higher-atherothrombotic risk vs. lower-atherothrombotic risk undergoing coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Trial
- Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022Trial
- Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.European heart journal · 2022Trial
- State-of-the-Art Review on Finite Element Analysis Applied to Ultrathin-Strut Drug-Eluting Stents: Examining the Present and Looking Ahead to the Future.Bioengineering (Basel, Switzerland) · 2026Review
- Practical Management in Coronary In-Stent Restenosis: A Narrative Review.Journal of clinical medicine · 2026Review
- Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in US Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW VII Trial.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis.Frontiers in cardiovascular medicine · 2026Article
- One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions.Frontiers in cardiovascular medicine · 2026Article
- Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with ultrathin-strut drug-eluting stents in South Korea: 3-year outcomes of the multicentre, randomised HOST-IDEA trial.EClinicalMedicine · 2026Article
- Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Consistency of primary outcomes in evidence synthesis researches on drug-eluting stents for coronary artery disease.BMC medical research methodology · 2025Article
- Bioresorbable Scaffolds for Coronary Revascularization: From Concept to Clinical Maturity.Journal of cardiovascular development and disease · 2025Review
- Review
- Safety and efficacy of Evermine50 Everolimus-eluting coronary stent system in patients with native coronary artery lesions: Three-year outcomes from a single-center.Journal of cardiovascular and thoracic research · 2025Article
- Drug-coated balloon angioplasty or drug-eluting stent implantation? a focus after the REC-CAGEFREE1 trial.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Optimizing Angioplasty in Elderly Patients with Multimorbidity: A Paradigm Shift in Risk Assessment: Optimizing Angioplasty in Elderly Patients with Multimorbidity.Galen medical journal · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
Abstract
aimsContemporary 2nd-generation thin-strut drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. A previous meta-analysis of 10 randomized controlled trials (RCTs) with 11 658 patients demonstrated a 16% reduction in the 1-year risk of target lesion failure (TLF) with ultrathin-strut DES compared with conventional 2nd-generation thin-strut DES. Whether this benefit is sustained longer term is not known, and newer trial data may inform these relative outcomes. We therefore sought to perform an updated systematic review and meta-analysis of RCTs comparing clinical outcomes with ultrathin-strut DES (≤70 µm strut thickness) with conventional 2nd-generation thin-strut DES. METHODS AND
resultsWe performed a random-effects meta-analysis of all RCTs comparing ultrathin-strut DES to conventional 2nd-generation thin-strut DES. The pre-specified primary endpoint was long-term TLF, a composite of cardiac death, myocardial infarction (MI), or clinically driven target lesion revascularization (CD-TLR). Secondary endpoints included the components of TLF, stent thrombosis (ST), and all-cause death. There were 16 eligible trials in which 20 701 patients were randomized. The weighted mean follow-up duration was 2.5 years. Ultrathin-strut DES were associated with a 15% reduction in long-term TLF compared with conventional 2nd-generation thin-strut DES [relative risk (RR) 0.85, 95% confidence interval (CI) 0.76-0.96, P = 0.008] driven by a 25% reduction in CD-TLR (RR 0.75, 95% CI 0.62-0.92, P = 0.005). There were no significant differences between stent types in the risks of MI, ST, cardiac death, or all-cause mortality.
conclusionsAt a mean follow-up of 2.5 years, ultrathin-strut DES reduced the risk of TLF, driven by less CD-TLR compared with conventional 2nd-generation thin-strut DES, with similar risks of MI, ST, cardiac death, and all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.